J
Julio Saez-Rodriguez
Researcher at Heidelberg University
Publications - 389
Citations - 26367
Julio Saez-Rodriguez is an academic researcher from Heidelberg University. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 68, co-authored 336 publications receiving 19188 citations. Previous affiliations of Julio Saez-Rodriguez include University of Nebraska–Lincoln & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett,Elena J. Edelman,Sonja J. Heidorn,Christopher Greenman,Christopher Greenman,Anahita Dastur,King Wai Lau,Patricia Greninger,I. Richard Thompson,Xi Luo,Jorge Soares,Qingsong Liu,Francesco Iorio,Francesco Iorio,Didier Surdez,Li Chen,Randy J. Milano,Graham R. Bignell,Ah Ting Tam,Helen Davies,Jesse A. Stevenson,Syd Barthorpe,Stephen R. Lutz,Fiona Kogera,Karl P. Lawrence,Anne McLaren-Douglas,Xeni Mitropoulos,Tatiana Mironenko,Helen Thi,Laura Richardson,Wenjun Zhou,F Jewitt,Tinghu Zhang,Patrick O’Brien,Jessica L. Boisvert,Stacey Price,Wooyoung Hur,Wanjuan Yang,Xianming Deng,Adam Butler,Hwan Geun Choi,Jae Won Chang,José Baselga,Ivan Stamenkovic,Jeffrey A. Engelman,Sreenath V. Sharma,Sreenath V. Sharma,Olivier Delattre,Julio Saez-Rodriguez,Nathanael S. Gray,Jeffrey Settleman,P. Andrew Futreal,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Sridhar Ramaswamy,Ultan McDermott,Cyril H. Benes +57 more
TL;DR: It was found that mutated cancer genes were associated with cellular response to most currently available cancer drugs, and systematic pharmacogenomic profiling in cancer cell lines provides a powerful biomarker discovery platform to guide rational cancer therapeutic strategies.
Journal ArticleDOI
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
Marc van de Wetering,Hayley E. Francies,Joshua M. Francis,Joshua M. Francis,Gergana Bounova,Francesco Iorio,Apollo Pronk,Winan J. van Houdt,Joost van Gorp,Amaro Taylor-Weiner,Lennart Kester,Anne McLaren-Douglas,Joyce Blokker,Sridevi Jaksani,Sina Bartfeld,Richard Volckman,Peter van Sluis,Vivian S. W. Li,Sara Seepo,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Kristian Cibulskis,Scott L. Carter,Scott L. Carter,Aaron McKenna,Michael S. Lawrence,Lee Lichtenstein,Chip Stewart,Jan Koster,Rogier Versteeg,Alexander van Oudenaarden,Julio Saez-Rodriguez,Robert G.J. Vries,Gad Getz,Gad Getz,Lodewyk F. A. Wessels,Michael R. Stratton,Ultan McDermott,Matthew Meyerson,Matthew Meyerson,Mathew J. Garnett,Hans Clevers +41 more
TL;DR: Tumor organoids are amenable to high-throughput drug screens allowing detection of gene-drug associations and may fill the gap between cancer genetics and patient trials, complement cell-line- and xenograft-based drug studies, and allow personalized therapy design.
Journal ArticleDOI
A Landscape of Pharmacogenomic Interactions in Cancer
Francesco Iorio,Francesco Iorio,Theo A. Knijnenburg,Theo A. Knijnenburg,Daniel J. Vis,Graham R. Bignell,Michael P. Menden,Michael P. Menden,Michael Schubert,Nanne Aben,Nanne Aben,Emanuel Gonçalves,Syd Barthorpe,Howard Lightfoot,Thomas Cokelaer,Thomas Cokelaer,Patricia Greninger,Ewald van Dyk,Han Chang,Heshani de Silva,Holger Heyn,Xianming Deng,Regina K. Egan,Qingsong Liu,Tatiana Mironenko,Xeni Mitropoulos,Laura Richardson,Jinhua Wang,Tinghu Zhang,Sebastian Moran,Sergi Sayols,Maryam Soleimani,David Tamborero,Nuria Lopez-Bigas,Nuria Lopez-Bigas,Petra Ross-Macdonald,Manel Esteller,Manel Esteller,Nathanael S. Gray,Daniel A. Haber,Daniel A. Haber,Michael R. Stratton,Cyril H. Benes,Lodewyk F. A. Wessels,Lodewyk F. A. Wessels,Julio Saez-Rodriguez,Julio Saez-Rodriguez,Ultan McDermott,Mathew J. Garnett +48 more
TL;DR: It is reported how cancer-driven alterations identified in 11,289 tumors from 29 tissues can be mapped onto 1,001 molecularly annotated human cancer cell lines and correlated with sensitivity to 265 drugs.
Journal ArticleDOI
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
Fiona M. Behan,Francesco Iorio,Francesco Iorio,Gabriele Picco,Emanuel Gonçalves,Charlotte M. Beaver,Giorgia Migliardi,Rita Santos,Yanhua Rao,Francesco Sassi,Marika Pinnelli,Rizwan Ansari,Sarah Harper,David A. Jackson,Rebecca McRae,Rachel Pooley,Piers Wilkinson,Dieudonne van der Meer,David J. Dow,Carolyn Buser-Doepner,Andrea Bertotti,Livio Trusolino,Euan A. Stronach,Julio Saez-Rodriguez,Kosuke Yusa,Kosuke Yusa,Mathew J. Garnett +26 more
TL;DR: In a screen of 324 human cancer cell lines and utilising a systematic target prioritization framework, the Werner syndrome ATP-dependent helicase is shown to be a synthetic lethal target in tumours from multiple cancer types with microsatellite instability, providing a new target for cancer drug development.
Journal ArticleDOI
The Global Phosphorylation Landscape of SARS-CoV-2 Infection.
Mehdi Bouhaddou,Danish Memon,Bjoern Meyer,Kris M. White,Veronica V. Rezelj,Miguel Correa Marrero,Benjamin J. Polacco,James E. Melnyk,Svenja Ulferts,Robyn M. Kaake,Jyoti Batra,Alicia L. Richards,Erica Stevenson,David E. Gordon,Ajda Rojc,Kirsten Obernier,Jacqueline M. Fabius,Margaret Soucheray,Lisa Miorin,Elena Moreno,Cassandra Koh,Quang Dinh Tran,Alexandra Hardy,Rémy Robinot,Thomas Vallet,Benjamin E. Nilsson-Payant,Claudia Hernandez-Armenta,Alistair Dunham,Sebastian Weigang,Julian Knerr,Maya Modak,Diego Quintero,Yuan Zhou,Aurelien Dugourd,Alberto Valdeolivas,Trupti Patil,Qiongyu Li,Ruth Hüttenhain,Merve Cakir,Monita Muralidharan,Minkyu Kim,Gwendolyn M. Jang,Beril Tutuncuoglu,Joseph Hiatt,Jeffrey Z. Guo,Jiewei Xu,Sophia Bouhaddou,Christopher J.P. Mathy,Anna Gaulton,Emma J. Manners,Eloy Felix,Ying Shi,Marisa Goff,Jean K. Lim,Timothy McBride,Michael C. O’Neal,Yiming Cai,Jason C.J. Chang,David J. Broadhurst,Saker Klippsten,Emmie de Wit,Andrew R. Leach,Tanja Kortemme,Brian K. Shoichet,Melanie Ott,Julio Saez-Rodriguez,Benjamin R. tenOever,R. Dyche Mullins,Elizabeth R. Fischer,Georg Kochs,Robert Grosse,Adolfo García-Sastre,Marco Vignuzzi,Jeffery R. Johnson,Kevan M. Shokat,Danielle L. Swaney,Pedro Beltrao,Nevan J. Krogan +77 more
TL;DR: A quantitative mass spectrometry-based phosphoproteomics survey of SARS-CoV-2 infection in Vero E6 cells reveals dramatic rewiring of phosphorylation on host and viral proteins, revealing potential COVID-19 therapies.